arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Pyxis Oncology, Inc.

PYXS Health Care Biotechnology: Pharmaceutical Preparations
$3.83
▼ -1.5% Today
as of Sep 4, 16:53 ET
Last 30 days +33.68% Jul 27 → Sep 04
$2.55 $2.91 $3.27 $3.63 $3.99 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$3.53
High
$4.05
Low
$3.53
Volume
$2M
Avg Vol
$926,484
Mkt Cap
$260M
P/E (TTM)
—
Beta
—
52w High
$5.55
52w Low
$1.03
Div Yield
—
Shares Out
$63M

Recent Press Releases & News last 60 days · 3 items

Sep 1 · 11:30 PR GlobeNewswire
Pyxis Oncology to Participate in Upcoming Investor Conferences
Aug 13 · 11:00 PR GlobeNewswire
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Aug 3 · 11:11 MT Newswires
Wells Fargo Initiates Pyxis Oncology at Overweight With $12 Price Target

Overview

52-week range
$1.03
$5.55
62% of range
Avg surprise (last 3)
-3.2%
Avg reaction (last 2)
-6.0%
50% positive
Latest IV / EM
427%
EM ±66.7% · $5 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.56$-0.44$-0.31$-0.19$-0.06 Actual $-0.54Actual $-0.41Actual $-0.56Actual $-0.06Actual $-0.29Actual $-0.35Actual $-0.35Est $-0.29Actual $-0.30Est $-0.36Actual $-0.35Actual $-0.37Est $-0.35Actual $-0.40 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-25M$-18M$-11M$-4M$3M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.40 — — — — financials
Thu May 14, 2026Mar/2026 $-0.37 $-0.35 -5.7% -5.7% -15.6% earnings
Tue Sep 30, 2025Sep 2025 $-0.35 — — — — financials
Thu Aug 14, 2025Jun/2025 $-0.30 $-0.36 +16.7% — — earnings
Thu May 15, 2025Mar/2025 $-0.35 $-0.29 -20.7% — +3.7% earnings
Mon Sep 30, 2024Sep 2024 $-0.35 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.29 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.06 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.56 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.41 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.54 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————$3M———
Cost of revenue————————
Gross profit————————
Operating income$-26M$-24M—$-23M$-20M$-23M—$-24M
Net income$-25M$-23M—$-22M$-18M$-21M—$-21M
EPS (diluted)$-0.40$-0.37—$-0.35$-0.30$-0.35—$-0.35

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$19M$6M$15M$9M$11M$13M$19M$12M
Inventory————————
Total current assets$37M$46M$72M$83M$100M$112M$132M$149M
Total assets$55M$64M$92M$106M$123M$136M$157M$195M
Long-term debt————————
Total liabilities$43M$33M$38M$37M$36M$33M$36M$42M
Total equity$11M$31M$53M$69M$88M$103M$121M$154M

Implied volatility — last 90 days

77%435%794%1153%1512% Jun 07 — IV 406% · EM ±56.2%Jun 08 — IV 717% · EM ±94.7%Jun 09 — IV 756% · EM ±94.7%Jun 10 — IV 811% · EM ±95.8%Jun 11 — IV 921% · EM ±101.8%Jun 12 — IV 889% · EM ±90.9%Jun 15 — IV 1234% · EM ±89.3%Jun 16 — IV 1355% · EM ±80.0%Jun 17 — IV 1512% · EM ±63.2%Jun 26 — IV 135% · EM ±25.9%Jun 29 — IV 175% · EM ±30.9%Jun 30 — IV 248% · EM ±42.6%Jul 01 — IV 221% · EM ±36.8%Jul 02 — IV 106% · EM ±17.1%Jul 03 — IV 110% · EM ±17.1%Jul 06 — IV 139% · EM ±19.3%Jul 07 — IV 204% · EM ±26.9%Jul 08 — IV 267% · EM ±33.5%Jul 09 — IV 176% · EM ±20.8%Jul 10 — IV 220% · EM ±24.3%Jul 13 — IV 196% · EM ±16.4%Jul 14 — IV 91% · EM ±6.5%Jul 15 — IV 157% · EM ±9.3%Jul 20 — IV 132% · EM ±31.1%Jul 21 — IV 77% · EM ±17.9%Jul 22 — IV 143% · EM ±32.7%Jul 23 — IV 146% · EM ±32.8%Jul 24 — IV 147% · EM ±32.6%Jul 27 — IV 131% · EM ±27.3%Jul 28 — IV 109% · EM ±22.3%Jul 29 — IV 103% · EM ±20.5%Jul 30 — IV 178% · EM ±34.8%Jul 31 — IV 113% · EM ±21.7%Aug 03 — IV 116% · EM ±20.6%Aug 04 — IV 119% · EM ±20.6%Aug 05 — IV 167% · EM ±28.0%Aug 06 — IV 251% · EM ±40.7%Aug 07 — IV 475% · EM ±74.3%Aug 10 — IV 452% · EM ±62.7%Aug 11 — IV 187% · EM ±24.6%Aug 12 — IV 308% · EM ±38.6%Aug 13 — IV 332% · EM ±39.2%Aug 14 — IV 331% · EM ±36.5%Aug 17 — IV 396% · EM ±33.1%Aug 18 — IV 439% · EM ±31.8%Aug 19 — IV 1005% · EM ±59.3%Aug 20 — IV 1074% · EM ±44.9%Aug 24 — IV 121% · EM ±25.3%Aug 25 — IV 216% · EM ±44.1%Aug 26 — IV 142% · EM ±28.4%Aug 27 — IV 138% · EM ±27.1%Aug 28 — IV 356% · EM ±68.1%Aug 31 — IV 235% · EM ±41.7%Sep 01 — IV 312% · EM ±53.8%Sep 02 — IV 343% · EM ±57.3%Sep 03 — IV 442% · EM ±71.5%Sep 04 — IV 427% · EM ±66.7%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in